TRB
LIVE

Serial Number

79284012

Owner

TRB CHEMEDICA INTERNATIONAL SA

Attorney

Andrew M. Smith

Filing Date

Mar 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TRB Trademark

Serial Number: 79284012 • Registration: 6258760

TRB is a trademark filed by TRB CHEMEDICA INTERNATIONAL SA on March 11, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

TRB CHEMEDICA INTERNATIONAL SA (7 trademarks)

12, RUE MICHEL-SERVET
GENEVA CH-1206 , CH

Entity Type: 03

Trademark Details

Filing Date

March 11, 2020

Registration Date

February 2, 2021

Published for Opposition

November 17, 2020

Goods & Services

pharmaceuticals, namely, anti-neurodegenerative, anti-neurotrophic, anti-antineurotoxic, neuroprotective and neurorestorative effect agents; pharmaceuticals, namely, immunopharmaceuticals; medical and veterinary preparations, namely, preparations for use in treating joint disease in horses, and antioxidants; pharmaceutical and medicinal preparations and substances for treating and preventing ophthalmic, ocular, neurological, metabolic, dermatological, arthritic, cognitive, or sexual dysfunction-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for treating and preventing joint, ligament, tendon, cartilage, bone, damaged skin or tissue-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for the treatment of central or peripheral nervous system-related, spinal cord-related, or early stages of traumatic or acute vascular injury-related disorders and diseases; pharmaceutical and medicinal preparations and substances for the treatment of pain, inflammation, physical lesions, and wounds; analgesics; anti-inflammatories; medicines for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; medicines for use as surgical aid during cataract surgery procedures; medicines for the treatment of osteoarthritis and rheumatoid arthritis; medicines for the prevention of osteoporosis; medicines for the treatment of musculo-skeletal conditions, disorders or diseases; medicines for the treatment of tendinopathy; medicines for joint recovery after arthroscopy; medicines to help assist with the regeneration of ligament and tendon fibers; medicines for the treatment of immune system related diseases and disorders; medicines for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; pharmaceutical drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; pharmaceutical drugs for use as surgical aid during cataract surgery procedures; pharmaceutical drugs for the treatment of osteoarthritis and rheumatoid arthritis; pharmaceutical drugs for the prevention of osteoporosis; pharmaceutical drugs for the treatment of musculo-skeletal conditions, disorders or diseases; pharmaceutical drugs for the treatment of tendinopathy; pharmaceutical drugs for joint recovery after arthroscopy; pharmaceutical drugs to help assist with the regeneration of ligament and tendon fibers; pharmaceutical drugs for the treatment of immune system related diseases and disorders; pharmaceutical drugs for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; therapeutic drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic drugs for use as surgical aid during cataract surgery procedures; therapeutic drugs for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic drugs for the prevention of osteoporosis; therapeutic drugs for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic drugs for the treatment of tendinopathy; therapeutic drugs for joint recovery after arthroscopy; therapeutic drugs to help assist with the regeneration of ligament and tendon fibers; therapeutic drugs for the treatment of immune system related diseases and disorders, and therapeutic agents for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic agents for use as surgical aid during cataract surgery procedures; therapeutic agents for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic agents for the prevention of osteoporosis; therapeutic agents for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic agents for the treatment of tendinopathy; therapeutic agents for joint recovery after arthroscopy; therapeutic agents to help assist with the regeneration of ligament and tendon fibers; therapeutic agents for the treatment of immune system related diseases and disorders; transdermal patches featuring vitamins for increasing energy for medical use; biological cartilage, bone or skin tissue intended for subsequent implantation; biological preparations for medical or veterinary use, namely, for the treatment of infectious diseases; sanitary preparations for medical purposes; dietetic food and substances in the nature of food supplements and vitamins supplements all adapted for medical or veterinary use; food for babies; dietary supplements for humans and animals; meal replacements, namely, meal replacement bars adapted for medical use and meal replacement beverages adapted for medical use, and dietetic beverages adapted for medical and veterinary use; materials for dressings, namely, dressings for wounds, burns or surgery, adhesive bandages, gauze for dressings, pledgets; disinfectants

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 2, 2026 REM3
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 26, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 26, 2025 OPNR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Sep 18, 2024 CORR
CORRECTION TRANSACTION RECEIVED FROM IB
Jun 30, 2024 CRCV
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 9, 2024 ADCH
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 26, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 26, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 26, 2023 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 30, 2021 FINO
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 18, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 18, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 18, 2021 REAP
FINAL DISPOSITION NOTICE SENT TO IB
May 5, 2021 FICS
FINAL DISPOSITION PROCESSED
May 5, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 2, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 2, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 17, 2020 NPUB
PUBLISHED FOR OPPOSITION
Nov 17, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 28, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 8, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 7, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 7, 2020 TROA
REFUSAL PROCESSED BY IB
Jul 18, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 30, 2020 RFCS
REFUSAL PROCESSED BY MPU
Jun 30, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 29, 2020 RFCR
NON-FINAL ACTION WRITTEN
May 28, 2020 CNRT
ASSIGNED TO EXAMINER
May 21, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
May 1, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 23, 2020 REPR